Sponsored by
The following information summarizes selected treatment programs and related clinical trials for brain tumors.
Last updated: 5/13/26
ClinicalTrials.gov ID:
NCT05974410
Indication:
Recurrent glioblastoma.
Mechanism of Action:
Corticosteroid derivative that modulates the immune system, potentially enhancing anti-tumor immune responses.
ClinicalTrials.gov ID:
NCT05106296
Indication:
Pediatric brain cancer, including glioblastoma, DIPG, medulloblastoma, and ependymoma.
Mechanism of Action:
Combining ibrutinib and indoximod with chemotherapy to block the BTK and IDO pathways that tumors use to alter immune cell metabolism and suppress T-cell activity, with the goal of restoring a stronger anti-tumor immune response.
ClinicalTrials.gov ID:
Not available for expanded access program.
Indication:
Newly diagnosed and recurrent glioblastoma.
Mechanism of Action:
Dendritic cell vaccine loaded with autologous tumor mRNA and lysate, administered near tumor-draining lymph nodes.
Related Trial:
NCT06805305
Phase 2 for newly diagnosed glioblastoma.
ClinicalTrials.gov ID:
NCT06404034
Indication:
Recurrent glioblastoma.
Mechanism of Action:
Orally bioavailable gallium compound that disrupts iron metabolism in tumor cells, leading to inhibition of DNA synthesis and tumor growth.
Related Trial:
NCT04319276
Phase 1 in relapsed glioblastoma.
ClinicalTrials.gov ID:
Not available.
Indication:
Newly diagnosed glioblastoma.
Mechanism of Action:
IV-infused therapy that helps oxygen delivery to hypoxic tumor regions, with the goal of enhancing the effectiveness of radiation and chemotherapy.
ClinicalTrials.gov ID:
NCT06676891
Indication:
Recurrent glioblastoma.
Mechanism of Action:
Recombinant adenovirus carrying a modified ribozyme construct with the HSV-tk gene, targeting hTERT-positive glioblastoma cells.
ClinicalTrials.gov ID:
NCT04566393
Indication:
Advanced solid tumors with MAPK pathway alterations, including glioblastoma.
Mechanism of Action:
ERK1/2 inhibitor targeting the MAPK signaling pathway.